礼来公司投资45亿美元用于先进药物制造的新药铸造厂，以推动美国制药界的发展-动脉网

Eli Lilly Invests $4.5B In New Medicine Foundry for Advanced Drug Manufacturing To Push US Pharma Boundaries

benzinga 等信源发布 2024-10-02 09:06



可切换为仅中文







On Wednesday, Eli Lilly And Co. LLY announced a $4.5 billion investment to create the Lilly Medicine Foundry, a new center for advanced manufacturing and drug development.

周三，礼来公司（EliLilly And Co.LLY）宣布投资45亿美元，创建礼来医药铸造厂（LillyMedicineSfoundry），这是一个新的先进制造和药物开发中心。

As the company inches closer to becoming the first pharma company in the $1 trillion club, it aims to strengthen its standing as one of the top 10 most valuable firms in the U.S. by outpacing its competitors.

随着该公司距离成为这家价值1万亿美元俱乐部中的第一家制药公司越来越近，它的目标是通过超越竞争对手，巩固其在美国十大最具价值公司之一的地位。

In a report, Eli Lilly said it plans to reinvest its revenues into R&D, aiming to escape the pharmaceutical industry’s traditional boom-and-bust cycle.

礼来公司（EliLilly）在一份报告中表示，计划将收入再投资于研发，旨在摆脱制药行业传统的繁荣与萧条周期。

The company says the new facility will allow Lilly to research new ways of producing medicines while scaling up the manufacturing of medicines for clinical trials.

该公司表示，新设施将使礼来能够研究生产药物的新方法，同时扩大临床试验药物的生产规模。

Also Read: Eli Lilly’s Early Alzheimer’s Treatment Donanemab Scores Japanese Approval, Its Second Largest Market.

另请阅读：礼来公司的早期阿尔茨海默氏病治疗Donanemab获得了日本的认可，这是其第二大市场。

The Medicine Foundry will be the first-ever facility of its kind to combine research and manufacturing in a single location. It will be located in Indiana’s LEAP Research and Innovation District in Lebanon, Indiana, and will expand the company’s investment there to more than $13 billion.

该医药铸造厂将是有史以来第一个在单一地点将研究和制造结合起来的工厂。它将位于印第安纳州黎巴嫩的印第安纳州LEAP Research and Innovation District，并将公司在那里的投资扩大到130多亿美元。

This new facility will add to Lilly’s previous manufacturing commitments in Lebanon, which include a $2.1 billion investment announced in May 2022 to expand its network for active ingredients and new modalities, such as genetic medicines.

这家新工厂将增加礼来之前在黎巴嫩的制造承诺，其中包括2022年5月宣布的21亿美元投资，以扩大其活性成分和新模式（如基因药物）的网络。

In April 2023, the company announced an additional $1.6 billion investment.

2023年4月，该公司宣布追加16亿美元投资。

In May 2024, Lilly announced an additional $5.3 billion commitment to enhance its capacity to manufacture active pharmaceutical ingredients for its latest diabetes and obesity medicines, marking the largest single investment in active pharmaceutical ingredients production in U.S. history.

2024年5月，礼来宣布追加53亿美元的承诺，以提高其生产最新糖尿病和肥胖药物的活性药物成分的能力，这是美国历史上对活性药物成分生产的最大单笔投资。

Opening in late 2027, the facility will increase Lilly’s total capital commitment in the United States to more than $23 billion since 2020. It is trying to stay ahead of its close competitor, Novo Nordisk A/S NVO.

该设施将于2027年底开放，自2020年以来，礼来在美国的总资本承诺将增加到230多亿美元。它正试图领先于其竞争对手诺和诺德公司（NovoNordisk A/S NVO）。

Once fully operational, the Medicine Foundry is expected to add 400 full-time jobs.

一旦全面运营，该制药厂预计将增加400个全职工作岗位。

Price Action: At last check on Wednesday, LLY stock was down 0.39% at $881.00 during the premarket session.

价格走势：周三的最后一次检查显示，LLY股价在上市前下跌0.39%，至881.00美元。